ライフサイエンスコーパス: visual loss

1 cifically indicates the glaucomatous central visual loss.

2 , although at a slower pace than the rate of visual loss.

3 fects of acetazolamide in patients with mild visual loss.

4 valuating patients with suspected nonorganic visual loss.

5 derate risk for malignant transformation and visual loss.

6 in the differential diagnosis of nonorganic visual loss.

7 ctasis, associated with a medical history of visual loss.

8 ith 62.8% achieving visual success and 14.9% visual loss.

9 ccidental Closantel use is related to severe visual loss.

10 acuity (VA) in the evaluation of nonorganic visual loss.

11 ny RPE loss) is important to prevent central visual loss.

12 ay correlate and possibly predict functional visual loss.

13 sive subfoveal exudates and severe permanent visual loss.

14 involved in many ocular diseases that cause visual loss.

15 d avoid complications and further peripheral visual loss.

16 ly minimize late progression and the risk of visual loss.

17 ptly to minimize the risk for ulceration and visual loss.

18 aging technology can prevent progression and visual loss.

19 l approach in FMNS with infantile unilateral visual loss.

20 nsiderable morbidity and may cause permanent visual loss.

21 ool age group and are associated with severe visual loss.

22 patients with FMNS with infantile unilateral visual loss.

23 dative retinopathy, vitreous hemorrhage, and visual loss.

24 It can lead to significant visual loss.

25 Only 32% reported visual loss.

26 ese patients often have non-diabetes related visual loss.

27 entional treatment and can lead to permanent visual loss.

28 cterial keratitis remains a leading cause of visual loss.

29 nal detachment remains an important cause of visual loss.

30 udition by vision depends on the severity of visual loss.

31 aucomatous optic nerve damage and subsequent visual loss.

32 e were independent prognostic parameters for visual loss.

33 neuroretinal tissue, scarring, and permanent visual loss.

34 ly and tended to cause progressive, profound visual loss.

35 ath, which contributes to the persistence of visual loss.

36 r syndrome type 1B, which causes hearing and visual loss.

37 itudinal changes in RNFL thickness relate to visual loss.

38 ng the visual outcome is initial severity of visual loss.

39 nd is associated with clinically significant visual loss.

40 tional impairments as a consequence of their visual loss.

41 strategy to prevent further progression and visual loss.

42 cotoma, metamorphopsia, and mild to moderate visual loss.

43 ase characterized by a progressive bilateral visual loss.

44 be important in the management of nonorganic visual loss.

45 r syndrome type 1B, which causes hearing and visual loss.

46 essential in diagnosing a cerebral cause for visual loss.

47 L) in individuals with untreatable causes of visual loss.

48 inable transitions to severe laminopathy and visual loss.

49 this may progress to microbial keratitis and visual loss.

50 ive accumulation of droplets in CDK leads to visual loss.

51 to headache, seizure, confusion and frequent visual loss.

52 be required in an attempt to avoid permanent visual loss.

53 death from six adult subjects with monocular visual loss.

54 for progression to advanced AMD and related visual loss.

55 ndent and joint risk factors associated with visual loss.

56 nd can be useful in ascertaining reasons for visual loss.

57 intraocular inflammation is a major cause of visual loss.

58 d their degeneration results in irreversible visual loss.

59 s, pigmentary retinopathy, and retrochiasmal visual loss.

60 ptions are available to prevent irreversible visual loss.

61 es develop, which could produce irreversible visual loss.

62 roup and the role of amblyopia as a cause of visual loss.

63 order and the most leading cause of lifelong visual loss.

64 h basketball-related injury may cause severe visual loss.

65 toreceptor cell death associated with severe visual loss.

66 immunosuppressive drugs lowered the risk of visual loss.

67 angiography in a 66 years old man suffering visual loss.

68 of choroidal neovascular membrane (CNVM) and visual loss.

69 tive-day, she presented with sudden painful, visual loss.

70 sted, except for the subject with nonorganic visual loss.

71 ng to secondary glaucoma which may result in visual loss.

72 ease, intraocular pressure is raised without visual loss.

73 fully establish, the diagnosis of nonorganic visual loss.

74 with 63.6% achieving visual success and 8.2% visual loss.

75 Retinal detachment is an important cause of visual loss.

76 diseases such as glaucoma with irreversible visual losses.

77 change on OCT at increased risk of worsening visual losses.

78 ord recognition speed for people with severe visual loss (101 +/- 25%), while for those with moderate

79 tion in BEST1 and is associated with central visual loss, a characteristic retinopathy, an absent ele

80 diated disorder characterized by progressive visual loss, abnormal electroretinographic and visual fi

81 we identified common traits associated with visual loss across Malay, Indian, and Chinese individual

82 macular degeneration and a leading cause of visual loss after age 55.

83 criteria, biopsy results, and progression of visual loss after diagnosis.

84 The patients' severe visual loss after the injection was associated with ocul

85 ciated with increased risk of best-corrected visual loss (all P <= .027).

86 educed visual acuity secondary to nonorganic visual loss and bilateral ametropic amblyopia with strab

87 Uveitis is an important cause of functional visual loss and blindness in the developed world.

88 whether the relationship between severity of visual loss and changes in auditory abilities is proport

89 Rates of visual loss and complications among patients with RV wer

90 To describe factors that predict visual loss and complications in intermediate uveitis.

91 tal eye anomalies that can cause significant visual loss and cosmetic disfigurement in children.

92 etic counseling for prognostic estimation of visual loss and disease progression.

93 Fourteen patients with visual loss and mutated G11778A mitochondrial DNA.

94 h NF1-associated optic gliomas often develop visual loss and Nf1 genetically engineered mice with opt

95 To describe the incidence rates of visual loss and ocular complications in patients with re

96 Visual loss and ocular complications were common among H

97 Main outcome measures included rates of visual loss and ocular complications.

98 nner retinal neurons, and it also suppressed visual loss and optic atrophy induced by a mutant ND4 ho

99 a strong and consistent association between visual loss and smoking, independent of gender and alcoh

100 ritic pruning precedes the onset of clinical visual loss and structural changes in the optic nerve in

101 set of behavioural phenotypes in response to visual loss and the trained machine-learning algorithm s

102 improved estimate of the prospective time of visual loss and to a better timing of emerging therapies

103 ections may be associated with high rates of visual loss and/or mortality.

104 receptor disease with rod- and cone-mediated visual losses and thinning of the outer nuclear layer.

105 t presentation (median 16 days from onset of visual loss) and after 3, 6, 12 and 18 months.

106 in diagnosing optic neuropathies, nonorganic visual loss, and assessing visual function in infants or

107 thies) are some of the most common causes of visual loss, and can present in isolation or with associ

108 findings include headache, jaw claudication, visual loss, and constitutional symptoms (malaise, fever

109 mune uveoretinitis is a significant cause of visual loss, and mouse models offer unique opportunities

110 corneal decompensation, endophthalmitis, and visual loss are all important and some have recently bee

111 The development of CNV and visual loss are associated with lower choroidal circulat

112 appropriate procedures and to prevent severe visual loss as a result of neuroretinal damage.

113 do not like the term 'medically unexplained visual loss' as a diagnostic label.

114 xamined by an ophthalmologist and a cause of visual loss assigned to eyes with uncorrected acuity < o

115 incidence that presents with abrupt onset of visual loss associated with retinal vasculitis, retinal

116 achieved in 81%, although 38.5% had profound visual loss, associated with age older than 50 years and

117 to 33.7% at 1 year, and 92% avoided moderate visual loss at 1 year.

118 t remained stable, and 2 patients had severe visual loss at presentation that precluded assessment of

119 ent, and approximately 2 lines of additional visual loss at the conclusion follow-up.

120 Macular edema is a common cause of visual loss at uveitic patients.

121 categories, the crude incidence rate of any visual loss based on PVA and BCVA were 14.6 (95% confide

122 ed probability of subsequent progression and visual loss based on the validated risk score.

123 In one subject, monocular visual loss began at age 4 months, causing shrinkage of

124 6 infants who experienced varying degrees of visual loss but retained high behavioural plasticity, we

125 psing course suggested an increased risk for visual loss but was not statistically significant, perha

126 There were no patients who suffered visual loss, but 1 was left with mild symblephara near t

127 male presented with predominantly unilateral visual loss, but extensive bilateral visual field defect

128 cted patients present in infancy with severe visual loss, but may have some preservation of the photo

129 f affected patients so that those at risk of visual loss can be identified early and treated more agg

130 Cortical visual loss can be mistaken for FVL.

131 Overall, permanent visual loss can be observed and worse refractive outcome

132 ted controls to determine whether peripheral visual loss can lead to changes in gray matter volume.

133 nal detachment (RD) is associated with acute visual loss caused by anatomic displacement of the photo

134 l loss of accommodation (2-3 D), and no near visual loss compared with higher doses.

135 l, 8.39-19.23) likely to have best-corrected visual loss, compared with younger, nondiabetic individu

136 d in all studies" included visual acuity and visual loss, death of participants, and intraocular pres

137 Clinical features of NMO include visual loss, decreased coordination, widespread asthenia

138 come was undertaken, with visual success and visual loss defined as a gain or reduction of 0.3 logMAR

139 ated three patients in whom severe bilateral visual loss developed after they received intravitreal i

140 ement of the photoreceptors and with chronic visual loss/disturbance caused by retinal remodeling and

141 nto 4 groups based on increasing severity of visual loss (DOA1 to DOA4) and were stratified by OPA1 m

142 Thus, visual loss does pose a problem for a composer accustome

143 Since visual loss due to a brain tumor can be progressive and

144 lar edema (DME), is the most common cause of visual loss due to diabetes mellitus.

145 oconus affects 86 in 100 000 people, causing visual loss due to increasing irregular corneal astigmat

146 Fixational eye movements prevent and restore visual loss during fixation, yet the relative impact of

147 f pathologic RPE changes in the evolution of visual loss during long-term treatment with DFO.

148 ressively controlling known risk factors for visual loss, ensuring adherence to ophthalmologic treatm

149 ery which leads to high ocular morbidity and visual loss even with antibiotic treatment.

150 hy (TON) is a devastating cause of permanent visual loss following blunt injury to the head.

151 The fifth participant with visual loss for less than 12 months received the low dos

152 The fifth participant had visual loss for less than 12 months.

153 Four participants with visual loss for more than 12 months were treated.

154 ssionist painter Edgar Degas had progressive visual loss from a type of maculopathy during the last 4

155 ial proportion of the population at risk for visual loss from age-related macular degeneration consum

156 ntion that consistently prevents or reverses visual loss from diabetic macular edema in all patients.

157 recovery of visual function in patients with visual loss from GCA is poor.

158 risk for axonal degeneration and persistent visual loss from optic neuritis and multiple sclerosis.

159 Visual loss from optic neuropathy and ophthalmoplegia in

160 important, and the subsequent prevention of visual loss from PACG depends on an accurate assessment

161 s the standard treatment for reducing severe visual loss from proliferative diabetic retinopathy.

162 l have eye-related manifestations, including visual loss from the optic nerve and retinal disease, vi

163 Two of 9 patients had symptomatic visual loss from the scotoma because it involved the cen

164 luded and a positive diagnosis of functional visual loss (FVL) can be established.

165 group 2), and 2 participants with unilateral visual loss (group 3) were treated.

166 ter gain, final VA >/=20/40 or >/=20/25) and visual loss (>/=1 ETDRS line loss, >/=2 ETDRS line loss,

167 relationship between OCT characteristics and visual loss has not been well documented.

168 Patients with IIH with mild visual loss have typical symptoms, may have mild acuity

169 With visual loss, however, lamination was coarse and there wa

170 Personalized treatment reversed the visual loss, illustrating how proteomic tools may indivi

171 Visual loss impacted significantly on the lives of peopl

172 All patients with visual loss improved to normal visual function after sur

173 s of treatment group and initial severity of visual loss, improvement began within the first month.

174 grade was associated with increased rates of visual loss in a dose-dependent fashion.

175 ent study evaluates the causes and extent of visual loss in a group of patients with OFNF.

176 hthalmologist may be called upon to evaluate visual loss in a patient with posterior reversible encep

177 ention of angiogenesis, vascular leakage and visual loss in age-related macular degeneration.

178 rment is rapidly becoming a leading cause of visual loss in children in developed countries predomina

179 visual impairment (CVI) is a major cause of visual loss in children worldwide.

180 ion of these disorders can lead to long-term visual loss in children.

181 al visual impairment is a prevalent cause of visual loss in children.

182 urofibroma [OPPN]) can result in significant visual loss in children.

183 appears to decrease likelihood of stroke or visual loss in giant-cell arteritis without increasing b

184 cular degeneration (AMD), a leading cause of visual loss in older adults, has limited therapeutic opt

185 thought to contribute to the persistence of visual loss in optic neuritis and multiple sclerosis (MS

186 Severe visual loss in patients with age-related macular degener

187 tachment (NSD) remains an important cause of visual loss in patients with diabetes.

188 Photoreceptor apoptosis is a major cause of visual loss in retinal detachment (RD) and several other

189 We tested for rescue of visual loss in rodent eyes also injected with a mutant G

190 vent ischemic damage and halt progression of visual loss in the affected eye and prevent involvement

191 n (AMD) is the leading cause of irreversible visual loss in the elderly in developed countries and ty

192 ular degeneration (AMD) is a common cause of visual loss in the elderly, with increasing prevalence d

193 lateral NAION event based on the severity of visual loss in the first affected eye.

194 He complained of sudden painless profound visual loss in the left eye (LE) two hours after emboliz

195 mal prior retinal examination presented with visual loss in the right eye 2 months following confirme

196 y macular involvement and associated central visual loss in the third or fourth decade of life.

197 mblyopia was identified as the main cause of visual loss in the younger population.

198 Because visual loss in these patients often has a psychosocial b

199 he finding of different regional patterns of visual loss in these patients suggests that the optimal

200 retinitis in the macula were associated with visual loss in these patients.

201 gene therapy as a means of preventing severe visual loss in this condition.

202 Visual loss in this OFNF cohort was common, typically pr

203 explained 58.1% and 23.2% of best-corrected visual loss in this population, respectively.

204 a and reduced the rate of sustained moderate visual loss in those with moderately severe to very seve

205 among the most common causes of irreversible visual loss in uveitis.

206 lar degeneration (AMD) is a leading cause of visual loss in Western populations.

207 c atrophy, exudative disease, or AMD causing visual loss) in one or both eyes during the course of th

208 Determinants of visual loss included age, education, body mass index, sm

209 Some causes of visual loss (including congenital glaucoma with buphthal

210 Determination of the mechanisms by which visual loss increases mortality risk is important for de

211 of the retina is involved the risk of RD and visual loss increases significantly.

212 suppressive drug therapy lowered the risk of visual loss, independent of relapsing disease course (OR

213 Here we show that greater severity of visual loss is associated with increased auditory judgme

214 Visual loss is common in bacterial or fungal endophthalm

215 Visual loss is common in subjects with PIC, predominantl

216 ns with amblyopia suggest that much of their visual loss is due to active suppression of their amblyo

217 treatment with anti-VEGF therapies; although visual loss is modified in a portion of these cases, no

218 on and clinical management is imperative, as visual loss is often reversible with prompt treatment di

219 'Unexplained visual loss' is a useful working diagnosis until occult

220 ths (group 1), 6 participants with bilateral visual loss lasting less than 12 months (group 2), and 2

221 Six participants with chronic bilateral visual loss lasting more than 12 months (group 1), 6 par

222 way to decrease the risk of three causes of visual loss: macular edema, neovascularization, and reti

223 r investigation in regard to etiology of the visual loss may be appropriate.

224 Visual loss may be the result of orbital hemorrhage or d

225 Our data suggest that visual loss may occur during a preoccult phase of choroi

226 ing identified early-onset (aged </=3 years) visual loss (mean [SD] best-corrected visual acuity, +0.

227 cular necrotizing fasciitis may cause severe visual loss more often than previously recognized.

228 Development of CNVM, moderate visual loss (MVL) (</=20/50), and severe visual loss (SV

229 est-corrected visual acuity (BCVA), moderate visual loss (MVL; </=20/50), severe visual loss (SVL; </

230 It is unknown how severe visual losses need to be before changes in auditory abil

231 retinal disease (IRD) associated with severe visual loss, nystagmus, amaurotic pupils, oculo-digital

232 retinal ganglion cell (RGC) dysfunction and visual loss occur by unknown mechanisms.

233 xible pro re nata (PRN) regimen, progressive visual loss occurred exclusively in the group with prima

234 ity of the study group eyes (71%); permanent visual loss occurred in 4 eyes (1.7%).

235 Moderate visual loss occurred in 40 eyes (12.6%), with an inciden

236 Secondary visual loss occurs in millions of patients due to a woun

237 before disappearing, at which stage central visual loss occurs.

238 ous sinuses, and may result in more profound visual loss, ocular motor deficits, and hypopituitarism.

239 Visual loss of >2 Snellen lines occurred in 24 of 428 pa

240 442 incident cases of neovascular AMD with a visual loss of 20/30 or worse due primarily to AMD.

241 on initial presentation and to compare mean visual loss of firstly versus secondly affected eyes.

242 efined as the development of or worsening of visual loss of one or more categories.

243 ted imaging (DWI) in patients with monocular visual loss of presumed ischemic origin (MVL).

244 l allograft recipient was admitted for acute visual loss of the right eye.

245 isk ratio = 3.47, 95% CI: 1.24-8.70) to show visual loss of three or more lines than were eyes with a

246 resulting in diplopia, oscillopsia, blurred visual, loss of stereopsis, and reading fatigue.

247 and symptoms often include severe headache, visual loss, ophthalmoplegia, altered consciousness, and

248 ociated with a high morbidity from potential visual loss or rapid progression of latent systemic dise

249 were associated with >/= 2 Snellen lines of visual loss (P < .01) and visual acuity loss to 20/50 or

250 drugs was associated with a reduced risk of visual loss, particularly for the </=20/50 outcome (haza

251 On average participants with severe visual losses perceived sounds to be twice as far away,

252 acceptable, and most subjects with profound visual loss perform better on visual tasks with system t

253 ecovery usually follows the acute episode of visual loss, persistent visual deficits are common and a

254 Perioperative visual loss (POVL) is an uncommon complication primarily

255 Symptoms can include headaches, visual loss, pulsatile tinnitus, and back and neck pain,

256 our understanding of the natural history of visual loss, recovery, and recurrence in these disorders

257 adenosine triphosphate synthesis, suppressed visual loss, reduced apoptosis of retinal ganglion cells

258 Anesthesiologists developed a Postoperative Visual Loss Registry in an effort to better understand a

259 ge and lowering of intraocular pressure, the visual loss remained.

260 local and systemic long-term therapy, severe visual loss resulted in the majority of treated eyes and

261 eyes) with >or=6 months follow-up, eyes with visual loss showed greater RNFL thinning compared to eye

262 hen stratifying by mean deviation, with mild visual loss, size V was most sensitive, followed by STP;

263 Sustained moderate visual loss (SMVL) was defined as a 15-letter or more re

264 in different patients and in detecting other visual losses such as those associated with glaucoma.

265 inal appearance and a similar early onset of visual loss, suggesting both impaired retinal developmen

266 n loss has occurred may reduce the amount of visual loss sustained with anti-vascular endothelial gro

267 ate visual loss (MVL) (</=20/50), and severe visual loss (SVL) (</=20/200).

268 moderate visual loss (MVL; </=20/50), severe visual loss (SVL; </=20/200).

269 Early visual loss that began at 3 mo and progressed to blindne

270 nvestigation and management of patients with visual loss that cannot be accounted for by organic path

271 kinetic fields revealed regional patterns of visual loss that suggested a disease sequence.

272 ly important, including the mode of onset of visual loss, the presence of pain with eye movements, th

273 In patients with IIH and mild visual loss, the use of acetazolamide with a low-sodium

274 In 1 patient with progressive, idiopathic visual loss, this last-line analysis implicated retinal

275 ng and health care productivity and reducing visual loss through early treatment.

276 ange: 1-6) appeared to have greater risk for visual loss to 20/50 (odds ratio [OR] = 2.07; 95% CI, 0.

277 44 months (range: 1-153 months), the rate of visual loss to 20/50 or worse was 0.13 per eye-year (/EY

278 patients with FMNS with infantile unilateral visual loss underwent strabismus surgery to correct an A

279 l amblyopes, even those with the most severe visual loss, veridically matched all blurred edges, incl

280 p = 0.04), in MVL characterized by permanent visual loss versus transient symptoms (33 vs 18%, p = 0.

281 Visual loss was associated with a marked impact on healt

282 sual cortex were absent, suggesting that the visual loss was attributable to a prenatal etiology with

283 More than 90% of visual loss was attributable to cataract and uncorrected

284 Incident visual loss was defined as the development of or worseni

285 The main cause of untreatable visual loss was glaucoma.

286 Visual loss was present in 3 patients and proptosis was

287 e damage to Meyer's loop was determined, and visual loss was quantified using Goldmann perimetry.

288 Causes of visual loss were classified using the World Health Organ

289 Regional patterns of visual loss were evident using dark-adapted static thres

290 nt independent risk factors for the incident visual loss were increasing age, female gender, illitera

291 Visual losses were predictably related to a decline in O

292 racterized by severe and rapidly progressive visual loss when caused by a mutation in the mitochondri

293 ent therapy against the background of severe visual loss, whereas it may be harder to detect incremen

294 assist in clarifying how drusen give rise to visual loss, which is currently not known.

295 lamide in 165 participants with IIH and mild visual loss who received a low-sodium weight-reduction d

296 l relatives in this Chinese family developed visual loss with a wide range of severity, ranging from

297 Patients were also more likely to experience visual loss with laser than with ranibizumab treatment.

298 amely visual disability (permanent bilateral visual loss with visual acuity of <6/36 in the best eye)

299 ign bodies (IOFBs) are an important cause of visual loss within the group of working age population.

300 ry cataract, the second most common cause of visual loss worldwide.